Body dysmorphic disorder (BDD) is a mental health disorder characterized by persistent preoccupation with one or more perceived flaws in physical appearance that other people do not observe or consider slight, accompanied by repetitive behaviors or mental acts and clinically significant distress or impaired functioning. Common manifestations include prolonged mirror checking, excessive grooming, repeated comparison, reassurance seeking, concealing perceived defects, and avoidance of photographs, social situations, school, or work. BDD belongs to the obsessive-compulsive and related disorders grouping in DSM-5-TR and ICD-11. Effective treatment commonly involves BDD-specific cognitive behavioral therapy (CBT), including exposure and response prevention, and, when indicated, selective serotonin reuptake inhibitors (SSRIs). Assessment must also address depression, other co-occurring disorders, functioning, and suicide risk. NICE clinical guidance; Byrne et al., 2026.
BDD concerns the psychological meaning, certainty, and repetitive processing of perceived appearance defects. The perceived detail may involve skin, hair, nose, teeth, facial symmetry, muscularity, or virtually any bodily feature. Suffering cannot be estimated from the objective visibility of an appearance characteristic. A compassionate clinical evaluation takes the distress seriously while examining the degree of preoccupation, associated rituals, avoidance, and consequences. Having acne, a scar, a disability, a visible difference, or a particular body shape does not in itself imply BDD.
What is body dysmorphic disorder?
The clinical core of BDD is a persistent conviction or fear that an aspect of appearance is defective, ugly, abnormal, or unacceptable. Attention repeatedly returns to the feared feature, and the person often feels compelled to investigate, conceal, compare, modify, or obtain certainty about it. Attempts to obtain relief tend to be short-lived, keeping the issue psychologically dominant. Diagnostic criteria require a particular pattern of preoccupation and response, rather than simply being unhappy with appearance. NICE.
The historical term dysmorphophobia described an appearance-focused fear; modern diagnostic classification recognizes BDD as an established psychiatric disorder. The name is sometimes casually abbreviated in online discussions as 'body dysmorphia.' In clinical work, the diagnostic name matters because body dissatisfaction, distorted body image, cosmetic dissatisfaction, and BDD refer to different degrees and configurations of experience.
How common is BDD?
A systematic review by Veale and colleagues estimated a weighted prevalence of 1.9% among adults in community samples and 2.2% among adolescents. Estimates were higher in certain clinical and cosmetic settings, reflecting selective recruitment and differences in assessment methods. These figures describe populations sampled in the underlying studies, not an individual person's diagnostic probability. Veale et al., 2016.
BDD can affect people of different sexes, genders, ages, cultures, and backgrounds. Some presentations differ by social expectations, available procedures, and concerns about muscularity or facial appearance. Cultural norms shape the content of feared defects, while the clinical evaluation focuses on the preoccupation, repetitive responses, suffering, and impact on daily life. Studies involving predominantly Western clinical samples provide an incomplete picture of global experiences.
Symptoms and lived experience
The defining symptoms form an interconnected cognitive, emotional, behavioral, and social pattern. A person may recognize that a fear is excessive, remain unsure whether the perceived defect is severe, or be firmly convinced it is obvious to everyone. The intensity of conviction varies and may change over time. Symptoms can consume hours and interfere with opportunities that matter to the person.
Persistent appearance preoccupation
BDD-related thoughts often feel intrusive, repetitive, and difficult to set aside. The person may replay photographs, mentally examine remembered comments, search for differences between facial angles, or anticipate others noticing a supposed defect. It is the scope and persistence of the process, together with associated behaviors and impairment, that make the concern clinically significant. A person may genuinely have a minor visible skin condition or facial asymmetry; BDD assessment examines how that feature becomes the center of disproportionate preoccupation.
Checking, reassurance, and mental rituals
Mirror checking may involve repeated close inspection under changing light, comparing sides of the face, examining skin, or studying reflections in windows and phones. Some people avoid mirrors altogether because a glimpse produces distress. Others repeatedly take and delete selfies, inspect recordings, solicit opinions, compare themselves with peers or influencers, or monitor perceived reactions. Mental counting, reconstruction of visual images, and comparison can serve the same repetitive function as observable rituals. These acts can briefly reduce anxiety while strengthening the perceived importance of appearance certainty.
Camouflaging and avoidance
Concealment can involve heavy makeup, particular clothing, hair positioning, facial hair, masks, or constant attention to posture. People may avoid daylight, cameras, swimming, intimate relationships, public speaking, medical appointments, travel, or meeting friends. In more severe presentations, daily routines become dominated by preparation and avoidance; some people stop attending school or work or become housebound. The clinical priority is the cost to life and freedom of action, not whether the grooming style itself is unusual.
Shame, anxiety, depression, and loss of functioning
Fear of being judged can become intense. Shame and self-criticism may impair relationships, concentration, sleep, and quality of life. BDD often co-occurs with depression, social anxiety, OCD, or other psychiatric conditions; clinicians assess each condition on its own evidence. An individual may arrive for treatment presenting only with depressed mood, social withdrawal, repeated dermatology visits, or requests for cosmetic intervention, so sensitive questions about appearance preoccupation are crucial.
Insight and conviction
DSM-5-TR allows specification of insight as good or fair, poor, or absent/delusional. This refers to the degree of conviction about BDD beliefs; absence of insight does not automatically establish a separate psychotic disorder. Assessment still looks for the appearance-centered preoccupation and repetitive responses. Clinicians also examine other psychotic symptoms and medical or substance-related explanations when indicated. The ability to engage with treatment varies, and discussion of beliefs should respect the person's suffering rather than engage in arguments about attractiveness.
Diagnostic criteria and clinical assessment
A trained mental health professional evaluates the full presentation through clinical interviewing, history, functional assessment, and relevant differential diagnosis. DSM-5-TR describes four central components: preoccupation with one or more perceived defects that others do not observe or see as slight; repetitive behaviors or mental acts in response to the concerns at some time during the disorder; clinically significant distress or impairment; and appearance concerns not better explained by concerns about body fat or weight in a person who meets criteria for an eating disorder. ICD-11 also recognizes BDD within obsessive-compulsive and related disorders. NICE clinical assessment recommendations.
The clinician asks how often thoughts occur, how much time they take, what the person does in response, whether images and reflections trigger rituals, and how symptoms affect work, school, relationships, finances, self-care, and access to health care. The interview explores onset, course, previous treatment, cosmetic procedure history, medical conditions, bullying or stigma exposure, substance use, and family context where relevant. The assessor examines suicidality directly and privately when possible.
Screening is a starting point, not a diagnosis
Brief tools such as the Body Dysmorphic Disorder Questionnaire (BDDQ) and adapted dermatology or aesthetic-surgery versions can identify people who need further examination. Validation in selected settings shows potential usefulness but is not a universal test of whether a person 'has BDD.' Different versions, populations, languages, and thresholds have different performance. A positive result warrants a professional diagnostic interview; a negative result does not override compelling clinical signs. Dufresne et al., 2001; review of diagnostic and screening tools, 2023.
The BDD-YBOCS, a clinician-rated adaptation of the Yale-Brown Obsessive Compulsive Scale, measures severity and change in appearance-related obsessions and compulsive behaviors. It is used in research and specialized care for tracking symptoms, not as a stand-alone replacement for diagnostic judgment. Insight measures and self-report symptom questionnaires add information but require interpretation within their validation settings. Phillips et al., 1997.
How a careful diagnostic conversation works
A useful interview first asks neutrally whether appearance worries have been occupying significant time or influencing daily choices. The clinician then invites description of the feared feature, thoughts, rituals, concealment, avoidance, degree of conviction, and how these processes began. Assessment includes examination of whether appearance concerns persist despite temporary reassurance or cosmetic changes. When there is a genuine dermatologic, dental, surgical, or other medical problem, appropriate physical evaluation remains part of responsible care.
BDD diagnosis is not based on a professional rating someone as attractive or unattractive. Nor does a diagnosis require finding a completely imaginary feature. The perception of a slight or ordinary variation may be associated with clinically significant preoccupation. Equally, a person confronting real disfigurement or appearance-related stigma can experience valid distress without BDD; the clinician examines the pattern, context, goals, and impairments rather than categorizing their body.
BDD, body dissatisfaction, and related disorders
Distinguishing neighboring clinical and psychological phenomena prevents false labels and directs people toward the right treatment.
Body dissatisfaction and general appearance anxiety
Body dissatisfaction is a negative appraisal of one's body or appearance. It is a common research construct and can vary across situations without constituting a psychiatric diagnosis. Appearance anxiety refers to worry about how one looks or may be judged. BDD becomes clinically relevant when appearance preoccupation, repetitive responses, and marked suffering or impairment form the disorder's pattern. The content of a worry alone does not differentiate these experiences; time, functional restriction, and rituals are informative.
Obsessive-compulsive disorder
BDD and OCD belong to the same related-disorders category and share features such as obsessive preoccupation, rituals, checking, avoidance, and difficulty tolerating uncertainty. In BDD, the central meaning is an appearance defect and its anticipated consequences; OCD can center on contamination, harm, symmetry, taboo thoughts, or other themes. Co-occurrence is possible and requires evaluation of both. The more detailed OCD–BDD diagnostic comparison belongs to the dedicated OCD vs Body Dysmorphic Disorder article, while OCD and BDD: connection and comorbidity addresses their clinical relationship.
Eating disorders and weight concerns
Anorexia nervosa, bulimia nervosa, and other feeding or eating disorders may involve concerns about shape, weight, body fat, and self-evaluation. When preoccupation is better explained by body fat or weight concerns in someone who meets eating-disorder criteria, diagnostic boundaries require particular attention. BDD may instead focus on facial features, skin, hair, size or definition of particular muscles, or other perceived defects. Both types of disorder can co-occur, and clinicians assess food intake, compensatory behaviors, nutritional status, and safety when relevant. Body size is not a diagnostic marker for either category.
Muscle dysmorphia
Muscle dysmorphia is a DSM-5-TR specifier of BDD in which the person is preoccupied with the belief that their body build is insufficiently large or muscular, often despite objective muscularity. Compulsive exercise, food and supplement practices, mirror behaviors, and social avoidance can occur. Differential assessment considers eating disorders, exercise-related harm, substance use, and other body-image problems. Excessive exercise alone does not establish muscle dysmorphia, and being athletic or pursuing strength training is not pathological.
Social anxiety disorder, depression, and psychosis
In social anxiety disorder, fear of negative evaluation may cover many aspects of performance and interaction. BDD concerns center specifically on perceived appearance defects, although social situations often activate them. Depression may cause pervasive worthlessness or hopelessness; BDD adds the distinctive appearance preoccupation and associated compulsive processes. When appearance beliefs seem delusional, the clinician considers insight specifiers and whether a separate psychotic illness is present. A person may meet criteria for more than one condition; a single symptom should not be forced into one explanation.
Gender identity and visible differences
Gender identity and gender-affirming care are distinct from BDD. Gender dysphoria involves distress associated with incongruence between experienced gender and assigned sex or associated sex characteristics, evaluated in its own clinical framework. BDD may coexist but is never inferred from transgender identity or seeking gender-affirming care. People with scarring, burns, congenital differences, disability, skin disorders, or injury may experience stigma and appearance distress; these experiences merit appropriate medical and psychosocial support without automatic psychiatric labeling.
Psychological mechanisms and the maintenance cycle
Cognitive behavioral models describe BDD as an interaction of selective attention, negative interpretations of appearance, emotionally powerful beliefs, and repetitive safety behaviors. The person may narrow attention to an isolated detail, experience the detail as globally defining their identity or worth, infer that others are scrutinizing it, and attempt to eliminate the resulting uncertainty. Short-term relief reinforces checking, reassurance, concealment, or avoidance, preventing fuller learning from real-world experiences.
Selective attention and visual processing
Experimental research has investigated whether people with BDD attend disproportionately to details rather than the overall configuration of faces or bodies. Some studies report atypical processing patterns, but tasks, samples, and methods vary; a single universal 'visual-processing defect' has not been established. Cognitive beliefs, attentional selection, emotional salience, and behavioral testing all contribute to a richer explanation than the claim that BDD is simply a problem with eyesight.
Beliefs about appearance and self-worth
Common maintaining beliefs concern perfection, social acceptability, rejection, humiliation, or an assumption that a visible flaw determines the person's value. Personal meaning differs: someone may fear looking abnormal, someone else may anticipate being rejected, and another may believe a particular feature makes social life impossible. The clinical formulation identifies these beliefs while recognizing that real appearance-based discrimination can occur. Distinguishing stigma from inaccurate individual predictions matters for ethical treatment.
Reassurance, social comparison, and checking
Reassurance from friends or clinicians can feel essential, yet its effect may last only minutes. Comparing photographs or inspecting a feature may increase attention to discrepancies, reinforce monitoring, and perpetuate dissatisfaction. Platforms that invite frequent selfies and filtering may provide additional triggers for some individuals; evidence is mixed on direct causal effects of specific algorithms, and these technologies do not by themselves diagnose or inevitably cause BDD. Broader psychological evidence on social media and body image should be distinguished from BDD-specific treatment research.
Development and vulnerability
BDD commonly emerges in adolescence, when bodily change, social visibility, identity formation, and peer evaluation are salient. Vulnerabilities may include perfectionistic beliefs, sensitivity to criticism, bullying or teasing, family or cultural messages, and coexisting anxiety or depression. Retrospective associations do not prove that one event caused a disorder. There is no validated single-cause biological, familial, or digital explanation. Developmental assessment should examine social environments and strengths alongside symptom patterns.
Consequences, clinical severity, and suicide risk
BDD can restrict education, employment, physical health care, relationships, and financial well-being. Repeated attempts to alter appearance may be costly, medically risky, or psychologically unrewarding. Some people remain socially engaged despite substantial hidden suffering; others experience severe functional impairment. Severity requires individualized evaluation, including the burden of symptoms, risks, resources, and coexisting psychiatric conditions.
Suicide risk warrants explicit attention. In a prospective clinical study following 185 people with BDD for up to four years, suicidal ideation occurred in a mean of 57.8% of participants per year, with an annual suicide-attempt rate averaging 2.6%. These are findings from a selected clinical cohort, not population-wide predictions or an individual's risk estimate. They underscore the importance of evaluating suicidal thoughts, plans, past behavior, depression, isolation, and immediate safety. Phillips and Menard, 2006.
Any current intent, plan, or inability to remain safe requires urgent local emergency or crisis assessment. Clinicians make a collaborative safety plan, arrange appropriate level of care, address access to potentially lethal means, and coordinate ongoing treatment. Family members and peers can help facilitate professional support while respecting privacy and autonomy. Treatment of BDD remains important even when other crises take short-term priority.
Evidence-based treatment for body dysmorphic disorder
BDD is treatable. Clinical guidelines recommend a stepped and individualized approach based on age, impairment, previous response, preferences, co-occurring conditions, and available expertise. The best-supported psychological treatment is BDD-specific CBT with exposure and response prevention (ERP); SSRIs also have controlled-trial evidence and guideline support. More severe illness may require combination treatment and specialist multidisciplinary care. Treatment response is meaningful but heterogeneous, and remission and functional recovery are monitored over time. NICE; Byrne et al., 2026.
Cognitive behavioral therapy specific to BDD
BDD-focused CBT begins with a shared formulation of the appearance-related beliefs, attention patterns, rituals, avoidance, and consequences. Therapists help people identify triggers and gradually reduce responses that maintain preoccupation. Intervention may include cognitive restructuring of rigid beliefs, attentional flexibility, exposure to feared situations, response prevention for checking or camouflage rituals, and relapse prevention. The plan adapts to the person's symptoms and life context instead of asking them merely to 'like their appearance.'
A 2024 meta-analysis of 11 randomized trials including 667 participants found significant benefits of CBT for BDD outcomes relative to comparison conditions, but reported substantial heterogeneity in many analyses. Accordingly, effect estimates should be read as evidence of benefit across studied contexts rather than a uniform personal outcome or proof that a single manual is optimal for everyone. Meta-analysis, 2024.
A 2026 systematic review and meta-analysis examined 40 psychotherapy studies, including 27 treatment studies and additional observational or longer-term evidence. Its reported pooled response estimates depended on analysis and definitions; the authors highlighted that retention differed across formats and that treatment credibility predicted outcome. Such pooled percentages cannot be treated as a guarantee for an individual or as a direct equivalence between different treatments without adequate head-to-head trials. Byrne, Pikoos, and Rossell, 2026.
What exposure and response prevention means
Exposure is a planned encounter with situations or uncertainty that ordinarily prompt avoidance or compulsive safety strategies: being visible in ordinary lighting, attending a social event without prolonged preparation, tolerating a photograph, or using a mirror in a different way. Response prevention reduces checking, repeated reassurance, excessive concealment, or mental review that would normally follow. Tasks are negotiated and graded; they are designed to create learning and restore functioning while preserving dignity and medical safety. ERP is best delivered with professional oversight when impairment is significant, insight is poor, or suicide risk is present.
Therapy may address mirror use by practicing a less judgmental, more balanced mode of observation; it can also focus on time budgets for grooming and avoidance. When bullying or discrimination is real, treatment combines support and problem-solving for external harms with work on BDD symptoms. Treatment success is reflected in increased flexibility, participation, and reduced disorder-related distress, rather than achieving an appearance ideal.
SSRIs and other medication
SSRIs are medications that affect serotonin signaling and are used in treating several psychiatric disorders. Controlled evidence for BDD includes a randomized placebo-controlled fluoxetine study, while an earlier crossover trial found clomipramine more effective than desipramine. The medication evidence base remains smaller than the literature for some other common disorders, and individual treatment plans need careful monitoring. Phillips et al., 2002; Hollander et al., 1999.
NICE recommends BDD-focused CBT for adults with mild impairment, either an SSRI or intensive CBT for moderate impairment, and combined SSRI plus CBT for severe impairment. For nonresponse, clinicians assess adequacy of treatment, adherence, side effects, comorbidities, and suicide risk before considering further trials or specialist referral. Guidance may differ between jurisdictions, and the licensed indications of individual drugs vary. Initiation, dosage, interactions, monitoring, and discontinuation belong to an authorized prescriber; abrupt medication changes can be harmful. NICE recommendations.
Patients and clinicians discuss potential adverse effects, interactions, possible initial worsening of anxiety, and ongoing follow-up. A person's conviction that an appearance defect is real does not in itself dictate an antipsychotic prescription. When unusual beliefs, co-occurring psychotic symptoms, or treatment resistance complicate care, specialist psychiatric assessment is appropriate.
Combined treatment and specialist care
Combined psychotherapy and medication may be appropriate when symptoms are severe, chronic, or inadequately responsive to a single intervention. Multidisciplinary teams can coordinate psychotherapy, psychiatric prescribing, family involvement, and management of co-occurring depression or eating pathology. A person with significant medical needs requires coordinated physical care as well. Consistency of treatment goals helps prevent parallel interventions from reinforcing checking or repeated cosmetic reassurance.
Treatment for adolescents and families
Symptoms may start before adulthood, but young people can struggle to describe their experiences because of shame or fear of dismissal. Assessment includes the young person's own account, school or peer functioning, family responses to reassurance requests, online experiences, depression, eating-related symptoms, and safeguarding considerations. A developmental formulation avoids assuming that every adolescent appearance worry is BDD.
NICE recommends age-adapted BDD-focused CBT with ERP, involving family or carers appropriately, as first-line treatment for children and adolescents. Medication decisions require specialist child and adolescent psychiatric assessment and careful monitoring; where an SSRI is indicated, it is generally used alongside psychotherapy. NICE includes specific safety monitoring for emerging self-harm or suicidal symptoms, especially at treatment initiation. NICE, recommendations for children and young people.
A pilot randomized controlled trial supports the feasibility and potential effectiveness of specialist CBT for adolescents while leaving uncertainty about optimal protocols and longer-term outcomes across different populations. Mataix-Cols et al., 2015.
Parents can participate by responding to distress with care while reducing patterns of repetitive appearance reassurance when a therapist recommends it. School personnel can address bullying and provide accommodations that support access to education. Family involvement is collaborative, age-appropriate, and mindful of privacy and the young person's autonomy.
Online treatment, apps, and access to care
Therapist-guided internet CBT has randomized-trial support as a way to deliver structured BDD treatment. In a 2016 trial of 94 adults, therapist-guided online CBT showed greater improvement than online supportive therapy, including a higher proportion meeting the trial's response criterion. Participants were selected and assessed within a structured research program, so results cannot automatically be extended to unsupervised apps, generic mental health chatbots, or conversational AI companions. Enander et al., 2016.
The 2026 psychotherapy synthesis also described potentially useful internet-delivered formats while noting differences in retention and engagement. Availability, therapist training, privacy, clinical monitoring, accessibility, and ability to refer rapidly for urgent risk are essential design considerations. Online interventions for low-risk users can improve access, but severe impairment, suicidality, poor insight, or complicated comorbidity may require closer and more intensive clinical contact. Byrne et al., 2026.
AI-based appearance editing and repeated algorithmic exposure may affect an individual's comparison environment, yet evidence specific to causal onset of BDD or efficacy of AI-led BDD therapy remains preliminary. Responsible evaluation separates clinical telepsychotherapy, evidence-tested digital CBT programs, general self-help apps, algorithmic beauty content, and AI chat interfaces into distinct categories. Therapeutic claims should be tied to studied interventions and populations.
Cosmetic procedures, dermatology, and dental care
BDD is clinically relevant to dermatology, cosmetic surgery, and dental services because appearance-focused requests may mask substantial distress. A person may pursue successive treatments, become preoccupied with new features, or feel disappointed even after a technically satisfactory procedure. Cosmetic procedures do not directly target the underlying compulsions and rigid appearance beliefs. Still, study outcomes vary, and research cannot support an absolute claim that every individual with BDD experiences the same result. Bowyer et al., 2016.
A 2024 systematic review and meta-analysis examining patients in aesthetic and reconstructive plastic surgery settings estimated BDD prevalence of 18.6% across included studies, with substantial variation across settings and methods. These studies do not imply that aesthetic treatment causes BDD or that everyone requesting surgery has it; they support careful mental health screening and coordinated care. Kaleeny and Janis, 2024.
Clinicians should evaluate decision-making capacity, realistic expectations, stability of treatment goals, and the relationship between the requested procedure and recurrent BDD beliefs. A positive screen leads to clinical assessment, not automatic moral judgment. Legitimate dermatologic, reconstructive, dental, disability-related, or gender-affirming medical needs should receive appropriate evaluation. If BDD is active, coordinating with mental health professionals can reduce avoidable harm while preserving the patient's medical autonomy.
Recovery and preventing recurrence
Recovery often involves reclaiming attention and daily activities: spending less time inspecting a detail, tolerating uncertainty about how others see one, participating in valued relationships, and pursuing education, work, recreation, or care previously avoided. Symptoms can fluctuate with stress or major life transitions. Relapse prevention identifies early warning signs such as expanding checking routines, growing dependence on reassurance, skipping social activities, or renewed searches for definitive cosmetic fixes.
A maintenance plan can include scheduled follow-up, continued use of CBT skills, reviewing goals beyond appearance, supporting healthy sleep and routines, and prompt reassessment when depression or risk intensifies. It can also include coordinated care for genuine medical conditions or discrimination experiences. A temporary return of intrusive thoughts is information for the treatment team rather than evidence that progress was meaningless.
When someone close to a person has BDD, listening without ridicule, taking impairment seriously, and helping arrange evidence-based care are constructive first steps. Repeated debates about whether a perceived defect is 'real' often provide limited relief. Family members benefit from guidance about supporting autonomy and responding to rituals without hostility.
What research establishes and what remains uncertain
Established clinical knowledge includes recognized diagnostic criteria, the importance of preoccupation and repetitive responses, substantial possible impairment, and the role of BDD-focused CBT and serotonergic medication in care. Stronger evidence comes from guidelines, randomized trials, and systematic syntheses; however, the certainty and applicability of individual estimates differ across outcomes and populations. NICE; Byrne et al., 2026.
Evidence is limited in several areas. Psychotherapy trials often have modest samples, differing control conditions, varied protocols, and inconsistent longer-term follow-up. A 2024 meta-analysis reported substantial heterogeneity, so comparing effect sizes across studies requires caution. Medication trials are relatively few. Research on outcomes among gender-diverse groups, disabled people, diverse cultural contexts, older adults, and people with visible differences remains incomplete; instruments must be validated for specific settings and languages. CBT meta-analysis, 2024.
Contested or preliminary questions include precise contributions of visual processing, the direction of some social-media associations, long-term effects of cosmetic interventions among carefully defined subgroups, optimal combined-treatment sequencing, and whether emerging digital tools deliver durable independent benefits. Observational studies of stigma, social comparison, and appearance-based experiences may be highly informative but do not alone establish a single causal pathway to clinical BDD.
Frequently asked questions
Can someone have BDD if they actually have an appearance difference?
Yes. BDD assessment does not require a feature to be wholly imaginary. It examines the degree and pattern of preoccupation, repetitive behavior, distress, impairment, and alternative explanations. A genuine medical condition or visible difference deserves appropriate care and should never be dismissed because psychological symptoms are also present.
Is body dysmorphic disorder the same as low self-esteem?
No. Low self-esteem can accompany many psychological difficulties and may be relevant to BDD, but BDD has specific diagnostic requirements involving perceived appearance flaws, repetitive responses, and clinically important consequences. Someone may have ordinary appearance dissatisfaction or low confidence without BDD.
Can BDD focus on one body part or shift between features?
Both patterns occur. Attention may remain concentrated on one perceived defect or extend to several features, sometimes changing over time. Clinical work investigates the common maintaining process and its consequences rather than assuming only one body feature matters.
Is BDD a form of OCD?
BDD and OCD are separate diagnoses classified together among obsessive-compulsive and related disorders. They share features, and people can experience both. The appearance-centered content of BDD and differential clinical evaluation remain important.
Can cosmetic surgery cure BDD?
Cosmetic treatment is not an established treatment for the core psychiatric syndrome. Some studies report selected patients experience improvements in satisfaction or some symptoms, while sustained and generalized improvement is uncertain and many individuals continue to experience distress. Evidence-based mental health assessment is important before irreversible procedures, especially when BDD signs are present.
Does BDD always involve mirrors?
No. Some individuals check repeatedly, while others avoid mirrors because looking is upsetting. Mental comparisons, reassurance seeking, photography behaviors, or other repetitive responses may serve the same function.
How long does treatment take?
Treatment duration varies with severity, comorbidity, format, access, and response. Clinical trials often test structured courses over weeks or months, while some people benefit from longer-term or combination care. A qualified clinician can review symptom measures and functioning to adapt treatment rather than promising a fixed timeline.
When should someone seek professional assessment?
An evaluation is appropriate when appearance thoughts consume substantial time, cause significant suffering, trigger repeated rituals or avoidance, interfere with education, work, or relationships, or drive repeated appearance-related medical consultations. Any suicidal thoughts or risk of harm call for prompt clinical attention. Early and compassionate recognition can reduce unnecessary delays in appropriate care.
Related Articles
Body Image and Appearance Psychology — scientific research chapter examines multidimensional body image, social mechanisms, stigma, and intervention frameworks that provide a broader context for BDD.
OCD vs Body Dysmorphic Disorder: Appearance Concerns, Rituals, Insight, and Treatment examines differential diagnosis and specific clinical distinctions.
OCD and Body Dysmorphic Disorder: Connection, Comorbidity, and Treatment considers overlapping mechanisms and the management of comorbidity.
Social Media and Body Image: Appearance Comparison, Ideals, and Mental Health provides evidence on digital appearance comparison, a potential contextual factor in appearance preoccupation.
Body Dysmorphic Disorder vs Body Dissatisfaction: What Is the Difference? — distinguishes BDD from ordinary appearance dissatisfaction.
Body Dysmorphic Disorder Screening: Tools and Clinical Assessment — reviews screening measures and the limits of BDD assessment.
CBT for Body Dysmorphic Disorder: Evidence and Treatment Approaches — analyzes evidence for specialized cognitive behavioral therapy for BDD.
References
Abdalla, M., et al. (2026). The efficacy of cognitive behavioural therapy in the management of body dysmorphic disorder: A systematic review and meta-analysis. Clinical Psychology and Psychotherapy. https://doi.org/10.1002/cpp.70218.
Bowyer, L., Krebs, G., Mataix-Cols, D., Veale, D., and Monzani, B. (2016). A critical review of cosmetic treatment outcomes in body dysmorphic disorder. Body Image. King's College London publication.
Byrne, E. H., Pikoos, T. D., and Rossell, S. L. (2026). A meta-analysis and systematic review examining efficacy, acceptability and patient retention in psychotherapy studies for the treatment of body dysmorphic disorder. Body Image, 56, 102025. https://doi.org/10.1016/j.bodyim.2025.102025.
Dufresne, R. G., Phillips, K. A., Vittorio, C. C., and Wilkel, C. S. (2001). A screening questionnaire for body dysmorphic disorder in a cosmetic dermatologic surgery practice. Dermatologic Surgery, 27(5), 457–462. https://doi.org/10.1046/j.1524-4725.2001.00190.x.
Enander, J., et al. (2016). Therapist guided internet based cognitive behavioural therapy for body dysmorphic disorder: Single blind randomised controlled trial. BMJ, 352, i241. https://doi.org/10.1136/bmj.i241.
Hollander, E., et al. (1999). Clomipramine vs desipramine crossover trial in body dysmorphic disorder: Selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Archives of General Psychiatry, 56(11), 1033–1039. https://doi.org/10.1001/archpsyc.56.11.1033.
Kaleeny, J. D., and Janis, J. E. (2024). Body dysmorphic disorder in aesthetic and reconstructive plastic surgery: A systematic review and meta-analysis. Healthcare, 12(13), 1333. https://doi.org/10.3390/healthcare12131333.
Mataix-Cols, D., et al. (2015). A pilot randomized controlled trial of cognitive-behavioral therapy for adolescents with body dysmorphic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 54(11), 895–904. https://doi.org/10.1016/j.jaac.2015.08.011.
National Institute for Health and Care Excellence. (2005, updated). Obsessive-compulsive disorder and body dysmorphic disorder: Treatment (CG31). https://www.nice.org.uk/guidance/cg31/chapter/Recommendations.
Phillips, K. A., Albertini, R. S., and Rasmussen, S. A. (2002). A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Archives of General Psychiatry, 59(4), 381–388. https://doi.org/10.1001/archpsyc.59.4.381.
Phillips, K. A., Hollander, E., Rasmussen, S. A., Aronowitz, B. R., DeCaria, C., and Goodman, W. K. (1997). A severity rating scale for body dysmorphic disorder: Development, reliability, and validity of a modified version of the Yale-Brown Obsessive Compulsive Scale. Psychopharmacology Bulletin, 33(1), 17–22. PubMed PMID 9133747.
Phillips, K. A., and Menard, W. (2006). Suicidality in body dysmorphic disorder: A prospective study. American Journal of Psychiatry, 163(7), 1280–1282. https://doi.org/10.1176/ajp.2006.163.7.1280.
Veale, D., Gledhill, L. J., Christodoulou, P., and Hodsoll, J. (2016). Body dysmorphic disorder in different settings: A systematic review and estimated weighted prevalence. Body Image, 18, 168–186. https://doi.org/10.1016/j.bodyim.2016.07.003.
Zhao, F., Guo, Z., Bo, Y., Feng, L., and Zhao, J. (2024). Is cognitive behavioral therapy an efficacious treatment for psychological interventions in body dysmorphic disorders? A meta-analysis based on current evidence from randomized controlled trials. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2024.02.004.